強迫性精神官能症藥物市場：按類型、應用分類 - 全球預測 2025-2030

2023年強迫性精神官能症藥物市場價值為8.9626億美元，預計到2024年將達到9.6971億美元，複合年成長率為8.59%，到2030年將達到15.9592億美元。

強迫性精神官能症(OCD) 藥物市場是指旨在緩解強迫症相關症狀的藥物，強迫症是一種以強迫行為和侵入性思想為特徵的精神疾病。強迫症症狀的持續性強調了對這些藥物的需求，這些症狀嚴重影響日常功能和生活品質。一般來說，選擇性血清素再回收抑制劑（SSRI）和非典型抗精神病藥物是控制強迫症症狀的主要治療方法，同時也常使用認知行為療法（CBT）等心理療法。醫院、診所和門診診所是進行這些治療的主要最終使用地點。

影響市場的成長要素包括心理健康意識的提高、強迫性精神官能症盛行率的上升以及藥物開發技術的進步。此外，對青少年和兒童的興趣日益濃厚也為市場擴張提供了機會。然而，該市場受到藥品價格高、長期使用藥物帶來的副作用以及對某些患者療效有限等因素的阻礙。監管挑戰和對新治療方法的需求也構成了重大障礙。

副作用較少、療效較高的下一代藥物的開發可能會推動強迫症治療的市場開拓。根據個人的基因譜量身訂做治療計畫的個人化醫療方法也有潛力。使用數位健康工具來提高患者依從性和監測治療結果也是一個有前景的領域。隨著醫藥產業競爭格局的加劇，企業可以透過積極投資研發、建立聯合藥物開發的策略夥伴關係關係來掌握潛在商機。隨著市場競爭的加劇，專注於探索先進製劑、新的生化治療途徑、解決難治性患者未滿足需求的企業將擁有顯著優勢。儘管面臨挑戰，強迫症治療市場是一個由臨床需求和技術進步驅動的動態市場。

市場動態：快速發展的強迫性精神官能症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變強迫性精神官能症藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

• 市場促進因素
  • 強迫性精神官能症患者數量增加
  • 人們對強迫性精神官能症及其治療的認知不斷提高
  • 強迫性精神官能症藥物優勢保險
• 市場限制因素
  • 專利藥品專利到期
• 市場機會
  • 增加政府對新藥研發的承諾與投資
  • 治療強迫性精神官能症的新藥認證數量增加
• 市場挑戰
  • 政府對藥品核准的嚴格規定

波特的五力：駕馭強迫性精神官能症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解強迫性精神官能症藥物市場的外部影響

外部宏觀環境因素在塑造強迫性精神官能症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解強迫性精神官能症治療藥物市場的競爭狀況

強迫性精神官能症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣強迫性精神官能症藥物市場供應商的績效評估

FPNV 定位矩陣是評估強迫性精神官能症藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了強迫性精神官能症治療藥物市場的成功之路

強迫性精神官能症藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

• 市場動態
  • 促進因素
    • 強迫性精神官能症病例數增加
    • 提高對強迫症及其治療的認知
    • 強迫症藥物優惠保險
  • 抑制因素
    • 專利藥品專利到期
  • 機會
    • 政府優惠政策加大新藥研發投入
    • 強迫症新療法的產品核可增加
  • 任務
    • 關於藥品核准的嚴格政府法規
• 市場區隔分析
• 波特五力分析
• PESTEL分析
  • 政治的
  • 經濟
  • 社群
  • 技術的
  • 合法地
  • 環境

第6章強迫性精神官能症治療藥物市場：依類型

• SSRI
• TCA

第7章強迫性精神官能症治療藥物市場：依應用分類

• 診所
• 醫院
• 調查機構

第8章 美洲強迫性精神官能症藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章：亞太地區強迫性精神官能症藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章 歐洲、中東和非洲強迫性精神官能症藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭格局

• 2023 年市場佔有率分析
• FPNV 定位矩陣，2023
• 競爭情境分析
• 戰略分析和建議

公司名單

• Abbott Laboratories
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• Aurobindo Pharma USA
• Biohaven Pharmaceutical Holding Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly, and Company
• GlaxoSmithKline PLC
• H. LUNDBECK A/S
• Lannett Co Inc.
• Lupin Pharmaceuticals, Inc.
• Mallinckrodt Pharmaceuticals
• Par Pharmaceutical, Apotex Inc.
• Pfizer Inc.
• Sebela Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatria Inc.
• Zydus Pharmaceuticals, Inc.

The Obsessive-Compulsive Disorder Drugs Market was valued at USD 896.26 million in 2023, expected to reach USD 969.71 million in 2024, and is projected to grow at a CAGR of 8.59%, to USD 1,595.92 million by 2030.

The market for Obsessive-Compulsive Disorder (OCD) drugs is defined by pharmaceutical products aimed at alleviating symptoms associated with OCD, a mental health disorder characterized by compulsive behavior and intrusive thoughts. The necessity for these drugs is underscored by the persistent nature of OCD symptoms, which can severely impact daily functioning and quality of life. Typically, selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics constitute the primary application for managing OCD symptoms, often used alongside psychological therapies like Cognitive Behavioral Therapy (CBT). Hospitals, clinics, and outpatient centers represent the primary end-use settings where these treatments are administered.

Growth factors influencing the market include increasing awareness about mental health, the rising prevalence of OCD, and advancements in drug development technology. Additionally, a growing focus on adolescent and pediatric populations presents opportunities for market expansion. However, the market is hindered by factors such as the high cost of medications, side effects associated with long-term drug use, and limited efficacy in a subset of patients. Regulatory challenges and the need for novel therapeutic approaches also pose significant barriers.

Innovation in the OCD drugs market could be driven by developing next-generation pharmaceuticals with lower side effects and higher efficacy. There is also potential in personalized medicine approaches that tailor treatment plans based on individual genetic profiles. Harnessing the power of digital health tools to enhance patient compliance and monitor treatment outcomes is another promising area. As competition in the pharmaceutical landscape increases, companies can capitalize on potential opportunities by investing in robust R&D initiatives and establishing strategic partnerships for drug co-development. While the market is competitive, businesses focusing on advanced drug formulations, exploring new biochemical pathways for OCD treatment, and addressing the unmet needs of refractory patients stand to gain a significant advantage. Despite its challenges, the OCD drug market remains dynamic, driven by both clinical needs and technological advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Obsessive-Compulsive Disorder Drugs Market

The Obsessive-Compulsive Disorder Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of obsessive-compulsive disorder cases
  • Increasing awareness about OCD and its treatment
  • Favorable insurance for OCD drugs
• Market Restraints
  • Patent expiry of the patented drugs
• Market Opportunities
  • Favorable government initiatives and increasing investment in R&D for novel drug product
  • Increasing product approvals for new OCD drugs
• Market Challenges
  • Strict government regulations for drug authorization

Porter's Five Forces: A Strategic Tool for Navigating the Obsessive-Compulsive Disorder Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Obsessive-Compulsive Disorder Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Obsessive-Compulsive Disorder Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Obsessive-Compulsive Disorder Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Obsessive-Compulsive Disorder Drugs Market

A detailed market share analysis in the Obsessive-Compulsive Disorder Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Obsessive-Compulsive Disorder Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Obsessive-Compulsive Disorder Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Obsessive-Compulsive Disorder Drugs Market

A strategic analysis of the Obsessive-Compulsive Disorder Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Obsessive-Compulsive Disorder Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals LLC, Apotex Inc., Aurobindo Pharma USA, Biohaven Pharmaceutical Holding Co. Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly, and Company, GlaxoSmithKline PLC, H. LUNDBECK A/S, Lannett Co Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Par Pharmaceutical, Apotex Inc., Pfizer Inc., Sebela Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatria Inc., and Zydus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Obsessive-Compulsive Disorder Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across SSRI and TCA.
• Based on Application, market is studied across Clinic, Hospital, and Research Institute.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of obsessive-compulsive disorder cases
    • 5.1.1.2. Increasing awareness about OCD and its treatment
    • 5.1.1.3. Favorable insurance for OCD drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Patent expiry of the patented drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable government initiatives and increasing investment in R&D for novel drug product
    • 5.1.3.2. Increasing product approvals for new OCD drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government regulations for drug authorization
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Obsessive-Compulsive Disorder Drugs Market, by Type

• 6.1. Introduction
• 6.2. SSRI
• 6.3. TCA

7. Obsessive-Compulsive Disorder Drugs Market, by Application

• 7.1. Introduction
• 7.2. Clinic
• 7.3. Hospital
• 7.4. Research Institute

8. Americas Obsessive-Compulsive Disorder Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Obsessive-Compulsive Disorder Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Obsessive-Compulsive Disorder Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Amneal Pharmaceuticals LLC
• 3. Apotex Inc.
• 4. Aurobindo Pharma USA
• 5. Biohaven Pharmaceutical Holding Co. Ltd.
• 6. Dr. Reddy's Laboratories Ltd.
• 7. Eli Lilly, and Company
• 8. GlaxoSmithKline PLC
• 9. H. LUNDBECK A/S
• 10. Lannett Co Inc.
• 11. Lupin Pharmaceuticals, Inc.
• 12. Mallinckrodt Pharmaceuticals
• 13. Par Pharmaceutical, Apotex Inc.
• 14. Pfizer Inc.
• 15. Sebela Pharmaceuticals, Inc.
• 16. Sun Pharmaceutical Industries Ltd.
• 17. Teva Pharmaceutical Industries Ltd.
• 18. Viatria Inc.
• 19. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. INDIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. INDIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. POLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. POLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023